In infants that developed CD, the serum phospholipid profile was altered at 4 months, long before any exposure to gliadin or any production of anti-tTg (tissue transglutaminase) antibodies, compared to their controls matched for the same genetic profile that during the 8 years of observation did not become celiac patients. This evidence concerns the gene TGM2 and Cowden disease.